Literature DB >> 9356556

DST studies in psychotic depression: a meta-analysis.

J C Nelson1, J M Davis.   

Abstract

OBJECTIVE: Although hypersecretion of cortisol has frequently been reported in psychotic depression, the findings have been mixed. The authors performed a meta-analysis of the existing studies to determine the significance of differences in nonsuppression of cortisol across studies.
METHOD: Fourteen studies that compared dexamethasone suppression test (DST) results in psychotic and nonpsychotic patients were examined, and a Mantel-Haenszel meta-analysis was performed. For comparison purposes, 19 studies of the DST with respect to melancholic/nonmelancholic and inpatient/outpatient distinctions were similarly reviewed.
RESULTS: This analysis indicated a highly significant probability that a greater rate of cortisol nonsuppression occurs in psychotic depression. The nonsuppression rate was substantially higher in patients with psychotic depression (64%) than in nonpsychotic patients (41%). In the 19 studies of melancholia, nonsuppression was less frequent (36%), and when inpatient/outpatient status was controlled, melancholic depression was not significantly associated with nonsuppression. In nonmelancholic outpatients with major depression, the nonsuppression rate was low (12%).
CONCLUSIONS: Among patients with major depression, psychotic depression is the subtype that is most closely associated with nonsuppression of cortisol on the DST. Hypercortisolemia is usually present in psychotic depression and may be important in understanding the pathophysiology of this syndrome.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9356556     DOI: 10.1176/ajp.154.11.1497

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  65 in total

1.  Stress-level cortisol treatment impairs inhibitory control of behavior in monkeys.

Authors:  D M Lyons; J M Lopez; C Yang; A F Schatzberg
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

2.  Could stress cause psychosis in individuals vulnerable to schizophrenia?

Authors:  Cheryl Corcoran; Lilianne Mujica-Parodi; Scott Yale; David Leitman; Dolores Malaspina
Journal:  CNS Spectr       Date:  2002-01       Impact factor: 3.790

3.  The mineralocorticoid receptor agonist, fludrocortisone, differentially inhibits pituitary-adrenal activity in humans with psychotic major depression.

Authors:  Anna Lembke; Rowena Gomez; Lakshika Tenakoon; Jennifer Keller; Gregory Cohen; Gordon H Williams; Fredric B Kraemer; Alan F Schatzberg
Journal:  Psychoneuroendocrinology       Date:  2012-06-21       Impact factor: 4.905

Review 4.  Psychotic major depression: a benefit-risk assessment of treatment options.

Authors:  Audrey R Tyrka; Lawrence H Price; Marcelo F Mello; Andrea F Mello; Linda L Carpenter
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

5.  The future of antidepressant pharmacotherapy.

Authors:  David Baldwin; Chris Thompson
Journal:  World Psychiatry       Date:  2003-02       Impact factor: 49.548

6.  Hypercortisolemic depression is associated with the metabolic syndrome in late-life.

Authors:  Nicole Vogelzangs; Kristen Suthers; Luigi Ferrucci; Eleanor M Simonsick; Alessandro Ble; Matthew Schrager; Stefania Bandinelli; Fulvio Lauretani; Sandra V Giannelli; Brenda W Penninx
Journal:  Psychoneuroendocrinology       Date:  2007-01-16       Impact factor: 4.905

7.  Decreased adrenocorticotropic hormone and cortisol responses to stress in healthy adults reporting significant childhood maltreatment.

Authors:  Linda L Carpenter; John P Carvalho; Audrey R Tyrka; Lauren M Wier; Andrea F Mello; Marcelo F Mello; George M Anderson; Charles W Wilkinson; Lawrence H Price
Journal:  Biol Psychiatry       Date:  2007-07-27       Impact factor: 13.382

Review 8.  Glucocorticoid inhibition in the treatment of depression: can we think outside the endocrine hypothalamus?

Authors:  Mitchel A Kling; Victoria H Coleman; Jay Schulkin
Journal:  Depress Anxiety       Date:  2009       Impact factor: 6.505

Review 9.  Glucocorticoid sensitivity in health and disease.

Authors:  Rogier A Quax; Laura Manenschijn; Jan W Koper; Johanna M Hazes; Steven W J Lamberts; Elisabeth F C van Rossum; Richard A Feelders
Journal:  Nat Rev Endocrinol       Date:  2013-10-01       Impact factor: 43.330

Review 10.  Human genetics of plasma dopamine beta-hydroxylase activity: applications to research in psychiatry and neurology.

Authors:  J F Cubells; C P Zabetian
Journal:  Psychopharmacology (Berl)       Date:  2004-04-16       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.